Table 1.

Summary of clinical presentation of 6 patients with pseudocirrhosis

Case	Agea, years	Type of malignancy	Site of metastasis	Chemotherapy regimen	Signs of portal hypertension	Status	Time between diagnosis and death, weeks
1	60	ER-positive, PR-positive breast cancer	Liver, CNS, bone, lungs, pleura and lymph nodes	Adriamycin, cyclophosphamide, tamoxifen, paclitaxel, bevacizumab, gemcitabine, vinorelbine, ixabepilone, capecitabine, fulvestrant and eribulin	Refractory ascites	Deceased	22
2	70	ER-positive, PR-positive, HER-2/neu negative breast cancer	Liver, bone, lungs, pleura, lymph nodes and spleen	Docetaxel, cyclophosphamide, anastrozole, fulvestrant, paclitaxel, gemcitabine, vinorelbine, ixabepilone, capecitabine, exemestane and everolimus	Ascites, peripheral edema, esophageal and gastric varices, portal gastropathy	Deceased	24
3	66	ER-positive, PR-positive, HER-2/neu negative breast cancer	Liver, bone	Docetaxel, cyclophosphamide, fulvestrant, paclitaxel, gemcitabine, capecitabine and ixabepilone	Ascites, splenomegaly	Deceased	23
4	60	ER-positive, PR-positive, HER-2/neu negative breast cancer	Liver, bone, adrenal glands, lymph nodes	5-FU, Adriamycin, cyclophosphamide, tamoxifen, letrozole, exemestane, everolimus, fulvestrant, anastrozole, capecitabine, eribulin and gemcitabine	None	Deceased	15
5	81	ER-positive, PR-positive, HER-2/neu negative breast cancer	Liver, bone	Anastrozole, fulvestrant, tamoxifen and paclitaxel	Ascites	Deceased	1
6	66	ER-negative, PR-negative, HER-2/neu overexpression	Liver, lungs	Docetaxel, carboplatin, trastuzumab, ado-trastuzumab emtansine, pertuzumab and gemcitabine	Ascites, bleeding esophageal varices, peripheral edema, and splenomegaly	Alive	n/a

^aCurrent age or at time of death. CNS = Central nervous system; n/a = not applicable.